Berenberg Bank set a €106.00 ($130.86) price objective on Merck KGaA (FRA:MRK) in a research report sent to investors on Monday morning. The brokerage currently has a buy rating on the healthcare company’s stock.

MRK has been the topic of a number of other reports. JPMorgan Chase & Co. set a €95.00 ($117.28) price target on shares of Merck KGaA and gave the company a neutral rating in a research note on Monday, February 26th. Warburg Research set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Wednesday, March 7th. Sanford C. Bernstein set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Wednesday, November 29th. Bank of America set a €95.00 ($117.28) price target on shares of Merck KGaA and gave the company a neutral rating in a research note on Wednesday, December 6th. Finally, Morgan Stanley set a €98.00 ($120.99) price target on shares of Merck KGaA and gave the company a neutral rating in a research note on Friday, December 1st. Twelve investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of €100.55 ($124.13).

How to Become a New Pot Stock Millionaire

Shares of Merck KGaA stock opened at €77.70 ($95.93) on Monday. The stock has a market cap of $10,070.00 and a PE ratio of 12.99. Merck KGaA has a 12 month low of €76.60 ($94.57) and a 12 month high of €115.00 ($141.98).

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/berenberg-bank-reiterates-106-00-price-target-for-merck-kgaa-mrk/1954749.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.